Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

NCT03179436 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

415

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: Quavonlimab
BIOLOGICAL: Pembrolizumab
DRUG: Pembrolizumab/Quavonlimab

Sponsor

Merck Sharp & Dohme LLC